Aileron Therapeutics

General Information

We are a clinical-stage biopharmaceutical company that is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Our lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers. ALRN-6924, which is currently being tested in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2.

Employees: 15
Founded: 2001
Contact Information
Address 281 Albany Street, Cambridge, MA 02139. US
Phone Number (617) 995-0900
Web Address
View Prospectus: Aileron Therapeutics
Financial Information
Market Cap $220.7mil
Revenues $0 mil (last 12 months)
Net Income $-18.8 mil (last 12 months)
IPO Profile
Symbol ALRN
Exchange NASDAQ
Shares (millions): 3.8
Price range $15.00 - $15.00
Est. $ Volume $56.3 mil
Manager / Joint Managers BofA Merrill Lynch/ Jefferies
CO-Managers William Blair/ Canaccord Genuity
Expected To Trade: 6/29/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change